Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Michael Jordan donates $10M to North Carolina medical center in honor of his mother - 2At least 171 measles cases confirmed in 9 states, CDC data shows
- 3Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- 4New York to require social media platforms to display mental health warnings
- 55 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- Ancient eggshells shed new light on crocodiles that hunted prey from trees
- NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- Seoul says sorry after unapproved drone flights into North Korea
- 2023's Best 10 Cell phone Advancements You Can't Miss
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
- Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
